Who owns Carmell Therapeutics Corp - US?
- Ticker: CTCX
- CUSIP Number: 142922103
Tip: Access positions for across all investors
Analyze quarterly positions in Carmell Therapeutics Corp - US with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Carmell Therapeutics Corp - US stock
Who bought or sold Carmell Therapeutics Corp - US this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Vanguard Group | 170k | $646k | 5% | Dec 2023 |
|
| Carnegie Mellon University | 103k | $393k | 0% | Dec 2023 |
|
| Citadel Advisors | 15k | $56k | -16% | Dec 2023 |
|
| Hubbell Strickland Wealth Management | 13k | $32k | 100% | Mar 2024 |
|
| UBS Group | 690.00 | $2.6k | 100% | Dec 2023 |
|
| Wells Fargo & Company | 119.00 | $452.997300 | 38% | Dec 2023 |
|
| Royal Bank of Canada | 67.00 | $0 | 100% | Dec 2023 |
|
| Bank of America Corporation | 2.00 | $8.000000 | 100% | Dec 2023 |
|
| Jpmorgan Chase & Co | 2.00 | $7.000000 | 100% | Dec 2023 |
|
Who sold out of Carmell Therapeutics Corp - US?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Goldman Sachs Group | Sep 2023 | 17k | $62k |